Norfluoxetine (hydrochloride)是Fluoxetine在肝脏中通过N-去甲基化产生的活性代谢物，具有口服活性。
Cas No.:57226-68-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Norfluoxetine (hydrochloride) is an active metabolite of fluoxetine produced in the liver via N-demethylation and has oral activity[1]. Norfluoxetine (hydrochloride) is mainly used in research on diseases such as depression, obsessive-compulsive disorder, bipolar disorder, epilepsy, and bulimia nervosa[2-3].
In vitro, Norfluoxetine (hydrochloride) (0.03-30µM) treatment of MCF-7 cells for 72 hours significantly inhibited cell proliferation at 15-30µM[4]. Norfluoxetine (hydrochloride) (10µM) treatment of primary microglia for 24-72 hours reduced protein levels in cell lysates, decreased cell viability, and increased the expression of caspase-3, an apoptosis marker, in microglia[5]. Norfluoxetine (hydrochloride) (0.01-20µM) treatment of estrogen receptor-positive T47D-KBluc human breast cancer cells for 24 hours significantly reduced cell viability at 15-20µM[6].
In vivo, Norfluoxetine (hydrochloride) (1, 5, and 10mg/kg; 12h; i.p.) in male C57BL/6 mice treated with MPTP (20mg/kg) inhibited MPTP-induced degeneration of dopamine neurons in the substantia nigra, protected DA neurons from MPTP neurotoxicity, and inhibited microglial activation and NADPH oxidase-derived oxidative stress in cells[7].
References:
[1]. Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation[J]. Clinical Pharmacology & Therapeutics, 2003, 73(4): 330-337.
[2]. Amsterdam J D, Fawcett J, Quitkin F M, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study[J]. American Journal of Psychiatry, 1997, 154(7): 963-969.
[3]. Kecskeméti V, Rusznák Z, Riba P, et al. Norfluoxetine and fluoxetine have similar anticonvulsant and Ca2+ channel blocking potencies[J]. Brain research bulletin, 2005, 67(1-2): 126-132.
[4]. Lupu D, Pop A, FIZEȘAN I, et al. In vitro effects of fluoxetine and norfluoxetine on breast cancer proliferation[J]. Far macia, 2017, 4: 532-536.
[5]. Dhami K S, Churchward M A, Baker G B, et al. Fluoxetine and its metabolite norfluoxetine induce microglial apoptosis[J]. Journal of Neurochemistry, 2019, 148(6): 761-778.
[6]. Lupu D, Pop A, Cherfan J, et al. In vitro modulation of estrogen receptor activity by norfluoxetine[J]. Clujul Medical, 2015, 88(3): 386.
[7]. Kim K I, Chung Y C, Jin B K. Norfluoxetine Prevents Degeneration of Dopamine Neurons by Inhibiting Microglia‐Derived Oxidative Stress in an MPTP Mouse Model of Parkinson’s Disease[J]. Mediators of inflammation, 2018, 2018(1): 4591289.
Norfluoxetine (hydrochloride)是Fluoxetine在肝脏中通过N-去甲基化产生的活性代谢物，具有口服活性[1]。Norfluoxetine (hydrochloride)主要应用于抑郁症、强迫症、双相情感障碍、癫痫及神经性贪食症等疾病的相关研究[2-3]。
在体外，Norfluoxetine (hydrochloride)（0.03-30µM）处理MCF-7细胞72小时，在15-30µM时显著抑制了细胞增殖[4]。Norfluoxetine (hydrochloride)（10µM）处理原发性小胶质细胞24-72小时，降低了细胞裂解物中的蛋白质水平，降低了细胞存活率，并提高了小胶质细胞中凋亡标志物切割半胱天冬酶3的表达[5]。Norfluoxetine (hydrochloride)（0.01-20µM）处理雌激素受体阳性T47D-KBluc人类乳腺癌细胞24小时，在15-20µM时显著降低细胞存活率[6]。
在体内，Norfluoxetine (hydrochloride)（1, 5, and 10mg/kg; 12h; i.p.）在MPTP（20mg/kg）处理后治疗雄性C57BL/6小鼠，能够抑制因MPTP导致的小鼠黑质中多巴胺神经元的退化，保护DA神经元免受MPTP的神经毒性，抑制小胶质细胞活化以及细胞中NADPH氧化酶衍生的氧化应激[7]。
| Cell experiment [1]: | |
Cell lines | Cortical microglia |
Preparation Method | Cortical microglia were prepared from the cerebral cortices of 1-day-old Sprague–Dawley rats. Cortical cultures of rat microglia were pretreated with fluoxetine (50 and 100μM) or Norfluoxetine (hydrochloride) (50μM) for 6h followed by exposure to LPS (100μg/ml) or vehicle as a control or for 24h. |
Reaction Conditions | 50μM; 6h |
Applications | Norfluoxetine (hydrochloride) attenuates LPS-induced activation of NADPH oxidase and NO production in cortical microglial cultures. |
| Animal experiment [1]: | |
Animal models | C57BL/6 mice (8- to 10-week-old) |
Preparation Method | Adult male C57BL/6 mice (8- to 10-week-old) were obtained from Daehan Biolink. All animals were allowed to acclimate to their new surrounding at least 7 days and maintained in a room 20-22°C on a 12-hour light/dark cycle with food and water available ad libitum before PBS and MPTP treatment. As previously described, mice were used for MPTP intoxication. MPTP (20mg/kg, free base) was dissolved in PBS and then intraperitoneally injected into mice for four times at 2-hour intervals. For norfluoxetine treatment, 1, 5, and 10mg/kg of the Norfluoxetine (hydrochloride) were intraperitoneally administered for 12 hours starting from the last MPTP injection. |
Dosage form | 1, 5, and 10mg/kg; 12h; i.p. |
Applications | Norfluoxetine (hydrochloride) can inhibit the degeneration of dopamine neurons in the substantia nigra of mice caused by MPTP treatment, protecting DA neurons from the neurotoxicity of MPTP. |
References: | |
| Cas No. | 57226-68-3 | SDF | |
| 别名 | 去甲氟西汀,Desmethylfluoxetine | ||
| 化学名 | γ-[4-(trifluoromethyl)phenoxy]-benzenepropanamine, monohydrochloride | ||
| Canonical SMILES | NCCC(C1=CC=CC=C1)OC2=CC=C(C(F)(F)F)C=C2.Cl | ||
| 分子式 | C16H16F3NO•HCl | 分子量 | 331.8 |
| 溶解度 | 30mg/mL in ethanol, 30mg/mL in DMSO, 30mg/mL in DMF | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0139 mL | 15.0693 mL | 30.1386 mL |
| 5 mM | 602.8 μL | 3.0139 mL | 6.0277 mL |
| 10 mM | 301.4 μL | 1.5069 mL | 3.0139 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet